Morphea
Zapobieganie i profilaktyka

Morfea, czyli twardzina ograniczona, to przewlekłe zapalne schorzenie tkanki łącznej charakteryzujące się nadmierną syntezą i odkładaniem kolagenu w skórze oraz narządach wewnętrznych. Wczesne rozpoznanie i ocena aktywności choroby za pomocą zwalidowanych skal klinicznych są kluczowe dla zapobiegania trwałym następstwom funkcjonalnym i kosmetycznym. Szczególnie istotne jest szybkie wdrożenie leczenia systemowego u pacjentów z morfeą linijną głowy, szyi i kończyn oraz uogólnioną, aby uniknąć deformacji, przykurczów i różnicy długości kończyn. Leczenie ukierunkowane jest na fazę aktywną choroby, gdyż faza „wypalenia” nie reaguje na immunosupresję, a ryzyko terapii przewyższa potencjalne korzyści.

Morfea – Profilaktyka i Zapobieganie

Morfea, znana również jako twardzina ograniczona (localized scleroderma), jest przewlekłym zapalnym schorzeniem tkanki łącznej o różnorodnych prezentacjach klinicznych, które dotyka zarówno dorosłych, jak i dzieci. Charakteryzuje się nadmierną syntezą kolagenu i jego odkładaniem w skórze oraz różnych narządach wewnętrznych.12 Ze względu na nieznane dokładne przyczyny choroby, nie istnieją specyficzne metody zapobiegania morfei.3

Znaczenie Wczesnej Diagnozy

Chociaż nie istnieje znany sposób zapobiegania morfei (ponieważ przyczyna jest nieznana), wczesne rozpoznanie i leczenie mają kluczowe znaczenie dla zapobiegania trwałym następstwom funkcjonalnym i kosmetycznym.45 Ponieważ choroba może prowadzić do trwałych następstw kosmetycznych i funkcjonalnych, kluczowa jest właściwa ocena aktywności choroby i szybkie wdrożenie odpowiedniego leczenia, zapobiegając tym samym późniejszym uszkodzeniom.6

Pacjenci powinni być świadomi swojego normalnego stanu skóry i natychmiast konsultować się z dermatologiem, gdy zauważą jakiekolwiek nieprawidłowości. Im wcześniej choroba zostanie zdiagnozowana, tym lepsze są szanse na satysfakcjonujący wynik leczenia.7 Regularne badania lekarskie są szczególnie ważne dla osób z predyspozycjami genetycznymi, ponieważ badania sugerują, że krewni osób z morfeą mogą mieć wyższe ryzyko wystąpienia innych chorób związanych z układem immunologicznym.8

Ocena Aktywności Choroby i Ryzyka

Właściwa ocena ciężkości choroby jest kluczowym krokiem w ocenie wszystkich pacjentów z morfeą, szczególnie w wariantach pediatrycznych. Nieprawidłowa ocena ciężkości może prowadzić do opóźnionego rozpoczęcia odpowiedniego leczenia systemowego, a tym samym do nieodwracalnych fizycznych i funkcjonalnych niepełnosprawności.9 Ocena aktywności choroby oparta na obecnie zwalidowanych skalach klinicznych jest kluczowym krokiem w początkowej ocenie pacjentów z morfeą.10

Należy zwrócić szczególną uwagę na pacjentów z grupy wysokiego ryzyka. Pacjenci z morfeą linijną głowy i szyi lub kończyn są narażeni na znaczne ryzyko deformacji twarzy, różnicy długości kończyn i przykurczów, dlatego powinni być leczeni systemowo.11 Podobnie, pacjenci z morfeą uogólnioną mogą mieć warianty powierzchowne lub głębokie, wymagające różnych podejść terapeutycznych.12

Leczenie Jako Forma Profilaktyki

Chociaż nie istnieje skuteczna ogólna profilaktyka morfei, odpowiednie leczenie może służyć jako forma profilaktyki wtórnej, zapobiegając progresji i nawrotom choroby. Morfea zwykle przechodzi przez dwa etapy: aktywną (zapalną) fazę i fazę „wypalenia”. Leczenie jest ukierunkowane na aktywną fazę, w nadziei na stabilizację wielkości istniejących zmian i zapobieganie pojawianiu się nowych.13

Pacjenci muszą być świadomi, że dotknięta skóra nigdy nie będzie wyglądać całkowicie normalnie. Należy im wyjaśnić, że leczenie jest skierowane na aktywną fazę choroby, w nadziei na zapobieganie powiększaniu się już istniejących zmian i rozwojowi nowych. Wypalona choroba raczej nie poprawi się po leczeniu immunosupresyjnym, dlatego ryzyko związane z tymi lekami nie jest uzasadnione w przypadku wypalonej choroby.14

Opcje Terapeutyczne w Prewencji Progresji

Wybór metody leczenia zależy od głębokości i zakresu zajęcia oraz aktywności klinicznej choroby.15 Obecne opcje terapeutyczne są jednak ograniczone, niespecyficzne dla choroby, a ich długotrwałe stosowanie często wiąże się z wieloma działaniami niepożądanymi.16

  • Miejscowe kortykosteroidy są najczęściej preferowanym leczeniem pierwszego rzutu w przypadkach morfei o ograniczonym zasięgu.17
  • Fototerapia jest opcją leczenia pierwszego rzutu dla rozległej lub szybko postępującej choroby bez głębokiego zajęcia i może być również rozważana u pacjentów z ograniczonym zajęciem, którzy nie reagują na leczenie miejscowe.18
  • Metotreksat (MTX) ma najwięcej dowodów na skuteczność, potwierdzoną randomizowanymi badaniami kontrolowanymi.19 W połączeniu z krótkim kursem steroidów systemowych jest terapią pierwszego rzutu dla morfei linijnej głowy i szyi lub kończyn.20
  • Mykofenolan mofetylu może być stosowany jako bezpieczna alternatywa w przypadku nietolerancji lub nieskuteczności MTX.21 Jest to skuteczna opcja leczenia dla pacjentów z różnymi typami morfei niereagującymi na fototerapię i metotreksat.22
  • 1,25-Dihydroksywitamina D3 (kalcytriol) powoduje zależne od dawki hamowanie wzrostu fibroblastów i syntezy kolagenu oraz ma liczne działania immunoregulacyjne.23 Kalcytriol może być stosowany jako korzystny środek w leczeniu uogólnionej morfei.24
  • Takrolimus miejscowy 0,1% jest zalecany w leczeniu morfei.25
  • Autologiczne przeszczepy tłuszczu są obecnie uważane za idealne leczenie nieaktywnej morfei linijnej twarzy.26

Monitorowanie Odpowiedzi na Leczenie

Do monitorowania odpowiedzi na leczenie stosuje się różne narzędzia pomiarowe.27 Bieżący brak skutecznych narzędzi oceny wyjaśnia, dlaczego nadal nie ma randomizowanych badań z podwójnie ślepą próbą, które wykazałyby faktyczną skuteczność większości leków proponowanych do leczenia morfei.28

Leczenie PCM (metotreksat z pulsami kortykosteroidów) okazało się skuteczne w kontrolowaniu morfei w krótkim i średnim okresie. Jednak ponieważ morfea jest chorobą przewlekłą charakteryzującą się okresowymi zaostrzeniami i okresami remisji, potrzebne są nowe strategie leczenia i badania długoterminowe.29

Styl Życia i Kontynuacja Opieki

Zrozumienie własnej choroby jest kluczową częścią skutecznego zarządzania nią, co dotyczy również morfei. Edukując się na temat swojego stanu, pacjenci mogą lepiej zrozumieć, czego się spodziewać i podejmować świadome decyzje dotyczące opcji leczenia.30

Jeśli lekarz przepisuje leki, takie jak kortykosteroidy, metotreksat lub mykofenolan mofetylu, pacjenci powinni również uzyskać informacje od farmaceuty. Farmaceuta może wyjaśnić typowe skutki uboczne, interakcje tych leków z innymi lekami oraz potrzebę stosowania metod antykoncepcji w celu zapobiegania ciąży podczas stosowania tych leków.31

Większość powikłań związanych z chorobą można zmniejszyć, wcześnie ją lecząc. Pacjenci powinni postępować zgodnie z zaleceniami zespołu opieki zdrowotnej dotyczącymi badań przesiewowych związanych z powikłaniami (oko, mózg, aspekty psychologiczne).32 Leczenie może zmniejszyć stan zapalny, zatrzymać rozprzestrzenianie się zmian i zapobiec pojawianiu się nowych zmian.33

Fizjoterapia jest opcją wartą rozważenia u pacjentów, u których morfea doprowadziła do przykurczów stawów i ograniczeń ruchu kończyn, chociaż prawdziwa użyteczność takiej terapii nie została wykazana w żadnych badaniach.34

Szczególne Rozważania dla Morfei Dziecięcej

Morfea dziecięca wiąże się z cięższym przebiegiem choroby i wyższym ryzykiem nawrotu, które może wystąpić nawet po latach remisji.35 Dlatego szczególnie ważne jest ścisłe monitorowanie dzieci z morfeą i wczesne wdrożenie odpowiedniego leczenia.

Leczenie dla dzieci poparte najwyższą jakością dowodów (na podstawie badań epidemiologicznych) to fototerapia i schemat PCMT (kombinacja pulsów kortykosteroidów z metotreksatem).36 Dziecko będzie miało najbardziej pozytywne rokowanie, jeśli jego stan zostanie wcześnie leczony, gdy po raz pierwszy otrzyma diagnozę.37

Celem leczenia morfei dziecięcej jest zatrzymanie stanu zapalnego, zapobieganie pogorszeniu się choroby i zmniejszenie tworzenia się twardej (włóknistej) tkanki. Leczenie jest unikalne dla każdego dziecka i zależy od ciężkości diagnozy.38

Podsumowanie

Chociaż nie istnieje znany sposób zapobiegania morfei, ponieważ przyczyna jest nieznana, wczesna diagnoza i interwencja terapeutyczna są kluczowe w zapobieganiu trwałym następstwom. Aktywna choroba wymaga agresywnego leczenia, podczas gdy wypalona choroba może wymagać głównie nadzoru i terapii ukierunkowanych na poprawę wyglądu i funkcji.3940

Niezależnie od zastosowanego schematu terapeutycznego, wszystkie typy morfei mają tendencję do postępu i nawrotów, szczególnie gdy początek następuje w dzieciństwie.41 Dlatego długoterminowe monitorowanie i dostosowywanie strategii leczenia są niezbędne dla optymalnego prowadzenia pacjentów z morfeą.

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

  1. 09.04.2026
  2. www.leksykon.com.pl

Materiały źródłowe

  • #1 Morphea: The 2023 update
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9969991/
    Morphea, also known as localized scleroderma, is a chronic inflammatory connective tissue disorder with variable clinical presentations, that affects both adults and children. […] Since the disease may progress to permanent cosmetic and functional sequelae, it is crucial to properly assess the disease activity and to initiate promptly the adequate treatment, thus preventing subsequent damage. […] The current therapeutic options are, however, limited, not disease-specific and their long-term use is often associated with several adverse events. […] Herein, we review the various clinical presentations of morphea, the most recent advances regarding its pathogenesis, as well as the many challenges that the clinicians encounter in disease diagnosis, severity assessment and appropriate treatment selection.
  • #2 Treatment of Generalized Morphea with Oral 1.25-Dihydroxyvitamin D3 | SpringerLink
    https://link.springer.com/chapter/10.1007/978-1-4615-4857-7_44
    Scleroderma is a chronic connective tissue disease characterized by excessive collagen synthesis and its deposition in the skin and various internal organs. […] 1.25-Dihydroxyvitamin D3 (1.25(OH)2 D3 causes inhibition of fibroblast growth, has a role in controlling collagen synthesis and deposition and has numerous immunoregulatory activities. […] The evolution of the patients condition during the 6 months therapy with calcitriol, suggests that it can be used as a beneficial agent in the treatment of generalized morphea. […] Recently, Hulshof et al. and Humbert et al. reported a beneficial effect of oral 1,25-dihydroxyvitamin D3 (calcitriol) in patients with morphea. […] 1,25 (OH)2 D3 causes dose-dependent inhibition of fibroblast growth and collagen synthesis, and has numerous immunoregulatory activities. […] Therefore, encouraged by the promising results in the literature, we decided to begin treatment with calcitriol in three patients with generalized morphea (disseminated localized scleroderma).
  • #3 Scleroderma Causes, Symptoms, Treatment, Medications, Prevention
    https://www.medicinenet.com/scleroderma/article.htm
    Is it possible to prevent scleroderma? There is no prevention method or diet to avoid or decrease the risk of scleroderma.
  • #4 Juvenile Localized Scleroderma Symptoms & Causes
    https://my.clevelandclinic.org/health/diseases/14857-juvenile-localized-scleroderma
    Theres no known way to prevent juvenile localized scleroderma since the cause is unknown. […] The goal of juvenile localized scleroderma treatment is to stop inflammation, keep the condition from getting worse and reduce the formation of hard (fibrous) tissue. Treatment is unique to each child and depends on how severe their diagnosis is. […] Your child will have the most positive outlook if their condition receives treatment early, when they first get their diagnosis.
  • #5 Morphea: The 2023 update
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9969991/
    Morphea, also known as localized scleroderma, is a chronic inflammatory connective tissue disorder with variable clinical presentations, that affects both adults and children. […] Since the disease may progress to permanent cosmetic and functional sequelae, it is crucial to properly assess the disease activity and to initiate promptly the adequate treatment, thus preventing subsequent damage. […] The current therapeutic options are, however, limited, not disease-specific and their long-term use is often associated with several adverse events. […] Herein, we review the various clinical presentations of morphea, the most recent advances regarding its pathogenesis, as well as the many challenges that the clinicians encounter in disease diagnosis, severity assessment and appropriate treatment selection.
  • #6 Morphea: The 2023 update
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9969991/
    Morphea, also known as localized scleroderma, is a chronic inflammatory connective tissue disorder with variable clinical presentations, that affects both adults and children. […] Since the disease may progress to permanent cosmetic and functional sequelae, it is crucial to properly assess the disease activity and to initiate promptly the adequate treatment, thus preventing subsequent damage. […] The current therapeutic options are, however, limited, not disease-specific and their long-term use is often associated with several adverse events. […] Herein, we review the various clinical presentations of morphea, the most recent advances regarding its pathogenesis, as well as the many challenges that the clinicians encounter in disease diagnosis, severity assessment and appropriate treatment selection.
  • #7 MORPHEA: A Skin Condition That Can Be Detrimental To Your Self-Confidence | Bangkok Hospital Headquarter
    https://www.bangkokhospital.com/en/content/get-to-know-morphea
    There is no protection against morphea. You need to be aware of your normal skin condition, and consult a dermatologist promptly when you notice any anomaly. The sooner the condition is addressed, the better the chances of a satisfactory outcome.
  • #8 Morphea – MD Searchlight
    https://mdsearchlight.com/skin-problems-and-treatments/morphea/
    Morphea is a relatively uncommon skin condition that both kids and adults could potentially get. The cause of Morphea is thought to be related to an issue with the body’s immune system. However, it’s important for patients to be aware that factors like injuries, exposure to radiation, and even wear and tear from rubbing against something could also play a part. There seems to be a genetic factor as well, meaning that it could run in families, and research suggests that relatives of someone with Morphea might have a higher chance of having other immune system-related conditions. […] Understanding one’s condition is a key part of managing it effectively, and this holds true for Morphea as well. By educating themselves about their condition, patients can better understand what to expect and make informed choices about their treatment options. If a doctor prescribes medications such as corticosteroids, methotrexate, or mycophenolate mofetil, it’s vital that patients also get information from a pharmacist. The pharmacist can explain typical side effects, how these medications might interact with other drugs, and the need for birth control methods to prevent pregnancy while on these medications. This can help increase patients’ willingness and ability to follow their prescribed treatment plan.
  • #9 Morphea: The 2023 update
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9969991/
    The correct assessment of disease severity is a crucial step in the evaluation of all patients with morphea, in particular in pediatric variants. An incorrect severity assessment may lead to a delayed initiation of appropriate systemic treatment, and thus to irreversible physical and functional disabilities. […] Disease activity assessment based on current validated clinical scores is a crucial step in the initial evaluation of patients with morphea. A late diagnosis or an incorrect severity assessment may lead to a delay of appropriate treatment, and thus to physical and functional disabilities as well as decreased quality of life. This applies in particular to pediatric morphea, especially the linear and deep types, where initiating adequate systemics is pivotal for achieving disease control and reducing subsequent damage. […] In addition, childhood morphea is associated with a more severe disease course and higher risk of relapse, the latter occurring even after years of remission.
  • #10 Morphea: The 2023 update
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9969991/
    The correct assessment of disease severity is a crucial step in the evaluation of all patients with morphea, in particular in pediatric variants. An incorrect severity assessment may lead to a delayed initiation of appropriate systemic treatment, and thus to irreversible physical and functional disabilities. […] Disease activity assessment based on current validated clinical scores is a crucial step in the initial evaluation of patients with morphea. A late diagnosis or an incorrect severity assessment may lead to a delay of appropriate treatment, and thus to physical and functional disabilities as well as decreased quality of life. This applies in particular to pediatric morphea, especially the linear and deep types, where initiating adequate systemics is pivotal for achieving disease control and reducing subsequent damage. […] In addition, childhood morphea is associated with a more severe disease course and higher risk of relapse, the latter occurring even after years of remission.
  • #11 Morphea: Evidence-based recommendations for treatment – Indian Journal of Dermatology, Venereology and Leprology
    https://ijdvl.com/morphea-evidence-based-recommendations-for-treatment/
    Patients with linear morphea of the head and neck or limbs are at significant risk of facial deformity, limb length discrepancy and contractures and should, therefore, be treated with systemic therapy. Based on the available evidence, methotrexate in combination with a short course of systemic steroids is first-line therapy. […] Patients with generalized morphea may have superficial or deep variants. In patients without lesions that cross joints, phototherapy is an appropriate first option. […] If the patient has not improved after 2-3 months, then switching therapy to methotrexate in combination with systemic steroids is a next step. If, after an additional 2-3 months the patient has not improved, I recommend a trial of MMF.
  • #12 Morphea: Evidence-based recommendations for treatment – Indian Journal of Dermatology, Venereology and Leprology
    https://ijdvl.com/morphea-evidence-based-recommendations-for-treatment/
    Patients with linear morphea of the head and neck or limbs are at significant risk of facial deformity, limb length discrepancy and contractures and should, therefore, be treated with systemic therapy. Based on the available evidence, methotrexate in combination with a short course of systemic steroids is first-line therapy. […] Patients with generalized morphea may have superficial or deep variants. In patients without lesions that cross joints, phototherapy is an appropriate first option. […] If the patient has not improved after 2-3 months, then switching therapy to methotrexate in combination with systemic steroids is a next step. If, after an additional 2-3 months the patient has not improved, I recommend a trial of MMF.
  • #13 Morphea: Evidence-based recommendations for treatment – Indian Journal of Dermatology, Venereology and Leprology
    https://ijdvl.com/morphea-evidence-based-recommendations-for-treatment/
    Morphea typically goes through two stages: an active (inflammatory) stage and a „burnt out” stage. Treatment is targeted at the active phase, in the hope of stabilizing the size of current lesions and preventing the occurrence of new lesions. […] Patients need to recognize that the involved skin will never look completely normal. They must be counseled that treatment is aimed at active disease in the hopes of preventing enlargement of already-present lesions and the development of new lesions. Burnt-out disease is unlikely to improve with immunosuppression and, therefore, the risks of these medications are not warranted in burnt-out disease. […] Patients with limited plaque morphea are at very low risk of facial deformity, limb length discrepancy and contractures and therefore should be treated with topical agents whenever possible. Based on the available data, active limited plaque morphea should be primarily treated with topical tacrolimus twice daily. If no response is seen after 8 weeks, therapy may be changed to lesion limited-phototherapy (NB-UVB, BB-UVA, UVA1, or topical psoralen and UVA), twice-daily occluded calipotriene, a combination of calcipotriol and betamethasone dipropionate once to twice a day or thrice-weekly topical imiquimod.
  • #14 Morphea: Evidence-based recommendations for treatment – Indian Journal of Dermatology, Venereology and Leprology
    https://ijdvl.com/morphea-evidence-based-recommendations-for-treatment/
    Morphea typically goes through two stages: an active (inflammatory) stage and a „burnt out” stage. Treatment is targeted at the active phase, in the hope of stabilizing the size of current lesions and preventing the occurrence of new lesions. […] Patients need to recognize that the involved skin will never look completely normal. They must be counseled that treatment is aimed at active disease in the hopes of preventing enlargement of already-present lesions and the development of new lesions. Burnt-out disease is unlikely to improve with immunosuppression and, therefore, the risks of these medications are not warranted in burnt-out disease. […] Patients with limited plaque morphea are at very low risk of facial deformity, limb length discrepancy and contractures and therefore should be treated with topical agents whenever possible. Based on the available data, active limited plaque morphea should be primarily treated with topical tacrolimus twice daily. If no response is seen after 8 weeks, therapy may be changed to lesion limited-phototherapy (NB-UVB, BB-UVA, UVA1, or topical psoralen and UVA), twice-daily occluded calipotriene, a combination of calcipotriol and betamethasone dipropionate once to twice a day or thrice-weekly topical imiquimod.
  • #15 Morphea: Clinical Considerations and Management – Journal of the Turkish Academy of Dermatology
    https://jtad.org/articles/morphea-clinical-considerations-and-management/doi/jtad.galenos.2020.70299
    Morphea, also known as localized scleroderma, is a sclerosing disease of unknown etiology that involves mainly dermal and subcutaneous layers of skin. […] Early diagnosis and treatment is crucial to minimize potential sequelae. […] The choice of treatment modality depends on the depth and extent of involvement and the clinical activity of the disease. […] Topical steroids are the most commonly preferred first line treatment for cases of morphea with limited involvement. […] Phototherapy is the first-line treatment option for extensive or rapidly progressing disease without deep involvement and can also be considered for patients with limited involvement that are unresponsive to topical treatment. […] Morphea lesions with deep involvement or lesions causing functional impairments should be treated with systemic therapies.
  • #16 Morphea: The 2023 update
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9969991/
    Morphea, also known as localized scleroderma, is a chronic inflammatory connective tissue disorder with variable clinical presentations, that affects both adults and children. […] Since the disease may progress to permanent cosmetic and functional sequelae, it is crucial to properly assess the disease activity and to initiate promptly the adequate treatment, thus preventing subsequent damage. […] The current therapeutic options are, however, limited, not disease-specific and their long-term use is often associated with several adverse events. […] Herein, we review the various clinical presentations of morphea, the most recent advances regarding its pathogenesis, as well as the many challenges that the clinicians encounter in disease diagnosis, severity assessment and appropriate treatment selection.
  • #17 Morphea: Clinical Considerations and Management – Journal of the Turkish Academy of Dermatology
    https://jtad.org/articles/morphea-clinical-considerations-and-management/doi/jtad.galenos.2020.70299
    Morphea, also known as localized scleroderma, is a sclerosing disease of unknown etiology that involves mainly dermal and subcutaneous layers of skin. […] Early diagnosis and treatment is crucial to minimize potential sequelae. […] The choice of treatment modality depends on the depth and extent of involvement and the clinical activity of the disease. […] Topical steroids are the most commonly preferred first line treatment for cases of morphea with limited involvement. […] Phototherapy is the first-line treatment option for extensive or rapidly progressing disease without deep involvement and can also be considered for patients with limited involvement that are unresponsive to topical treatment. […] Morphea lesions with deep involvement or lesions causing functional impairments should be treated with systemic therapies.
  • #18 Morphea: Clinical Considerations and Management – Journal of the Turkish Academy of Dermatology
    https://jtad.org/articles/morphea-clinical-considerations-and-management/doi/jtad.galenos.2020.70299
    Morphea, also known as localized scleroderma, is a sclerosing disease of unknown etiology that involves mainly dermal and subcutaneous layers of skin. […] Early diagnosis and treatment is crucial to minimize potential sequelae. […] The choice of treatment modality depends on the depth and extent of involvement and the clinical activity of the disease. […] Topical steroids are the most commonly preferred first line treatment for cases of morphea with limited involvement. […] Phototherapy is the first-line treatment option for extensive or rapidly progressing disease without deep involvement and can also be considered for patients with limited involvement that are unresponsive to topical treatment. […] Morphea lesions with deep involvement or lesions causing functional impairments should be treated with systemic therapies.
  • #19 Morphea: Clinical Considerations and Management – Journal of the Turkish Academy of Dermatology
    https://jtad.org/articles/morphea-clinical-considerations-and-management/doi/jtad.galenos.2020.70299
    Methotrexate (MTX) has the most evidence for efficacy, proven by randomized controlled studies. […] In case of intolerance to or ineffectiveness with MTX, mycophenolate mofetil may be used as a safe alternative treatment option. […] Autologous fat grafting is currently considered as ideal treatment for inactive linear morphea of the face.
  • #20 Morphea: Evidence-based recommendations for treatment – Indian Journal of Dermatology, Venereology and Leprology
    https://ijdvl.com/morphea-evidence-based-recommendations-for-treatment/
    Patients with linear morphea of the head and neck or limbs are at significant risk of facial deformity, limb length discrepancy and contractures and should, therefore, be treated with systemic therapy. Based on the available evidence, methotrexate in combination with a short course of systemic steroids is first-line therapy. […] Patients with generalized morphea may have superficial or deep variants. In patients without lesions that cross joints, phototherapy is an appropriate first option. […] If the patient has not improved after 2-3 months, then switching therapy to methotrexate in combination with systemic steroids is a next step. If, after an additional 2-3 months the patient has not improved, I recommend a trial of MMF.
  • #21 Morphea: Clinical Considerations and Management – Journal of the Turkish Academy of Dermatology
    https://jtad.org/articles/morphea-clinical-considerations-and-management/doi/jtad.galenos.2020.70299
    Methotrexate (MTX) has the most evidence for efficacy, proven by randomized controlled studies. […] In case of intolerance to or ineffectiveness with MTX, mycophenolate mofetil may be used as a safe alternative treatment option. […] Autologous fat grafting is currently considered as ideal treatment for inactive linear morphea of the face.
  • #22 Mycophenolate an effective option for morphea treatment | 2 Minute Medicine
    https://www.2minutemedicine.com/mycophenolate-an-effective-option-for-morphea-treatment/
    1. In patients with different types of morphea unresponsive to phototherapy and methotrexate, mycophenolate appears to be a safe and beneficial treatment option. […] This study represents the largest study to date evaluating the efficacy and safety of mycophenolate for morphea, and appears to support current recommendations for the drug to be a beneficial and largely safe agent for administration in patients unresponsive to phototherapy and methotrexate.
  • #23 Treatment of Generalized Morphea with Oral 1.25-Dihydroxyvitamin D3 | SpringerLink
    https://link.springer.com/chapter/10.1007/978-1-4615-4857-7_44
    Scleroderma is a chronic connective tissue disease characterized by excessive collagen synthesis and its deposition in the skin and various internal organs. […] 1.25-Dihydroxyvitamin D3 (1.25(OH)2 D3 causes inhibition of fibroblast growth, has a role in controlling collagen synthesis and deposition and has numerous immunoregulatory activities. […] The evolution of the patients condition during the 6 months therapy with calcitriol, suggests that it can be used as a beneficial agent in the treatment of generalized morphea. […] Recently, Hulshof et al. and Humbert et al. reported a beneficial effect of oral 1,25-dihydroxyvitamin D3 (calcitriol) in patients with morphea. […] 1,25 (OH)2 D3 causes dose-dependent inhibition of fibroblast growth and collagen synthesis, and has numerous immunoregulatory activities. […] Therefore, encouraged by the promising results in the literature, we decided to begin treatment with calcitriol in three patients with generalized morphea (disseminated localized scleroderma).
  • #24 Treatment of Generalized Morphea with Oral 1.25-Dihydroxyvitamin D3 | SpringerLink
    https://link.springer.com/chapter/10.1007/978-1-4615-4857-7_44
    Scleroderma is a chronic connective tissue disease characterized by excessive collagen synthesis and its deposition in the skin and various internal organs. […] 1.25-Dihydroxyvitamin D3 (1.25(OH)2 D3 causes inhibition of fibroblast growth, has a role in controlling collagen synthesis and deposition and has numerous immunoregulatory activities. […] The evolution of the patients condition during the 6 months therapy with calcitriol, suggests that it can be used as a beneficial agent in the treatment of generalized morphea. […] Recently, Hulshof et al. and Humbert et al. reported a beneficial effect of oral 1,25-dihydroxyvitamin D3 (calcitriol) in patients with morphea. […] 1,25 (OH)2 D3 causes dose-dependent inhibition of fibroblast growth and collagen synthesis, and has numerous immunoregulatory activities. […] Therefore, encouraged by the promising results in the literature, we decided to begin treatment with calcitriol in three patients with generalized morphea (disseminated localized scleroderma).
  • #25 Morphea in Childhood: An Update | Actas Dermo-Sifiliográficas
    https://actasdermo.org/en-morphea-in-childhood-an-update-articulo-S157821901830088X
    Morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corticosteroids, mycophenolate mofetil, bosentan, and topical imiquimod 5%. […] A variety of measuring tools are used to monitor response to treatment. […] The treatments for children supported by the highest quality of evidence (based on epidemiological studies) are phototherapy and the PCMT regimen. […] In summary, PCMT has been shown to be effective in the control of morphea in the short and medium term. However, since morphea is a chronic disease characterized by intermittent outbreaks and periods of remission, new treatment strategies and long-term follow-up studies are needed.
  • #26 Morphea: Clinical Considerations and Management – Journal of the Turkish Academy of Dermatology
    https://jtad.org/articles/morphea-clinical-considerations-and-management/doi/jtad.galenos.2020.70299
    Methotrexate (MTX) has the most evidence for efficacy, proven by randomized controlled studies. […] In case of intolerance to or ineffectiveness with MTX, mycophenolate mofetil may be used as a safe alternative treatment option. […] Autologous fat grafting is currently considered as ideal treatment for inactive linear morphea of the face.
  • #27 Morphea in Childhood: An Update | Actas Dermo-Sifiliográficas
    https://actasdermo.org/en-morphea-in-childhood-an-update-articulo-S157821901830088X
    Morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corticosteroids, mycophenolate mofetil, bosentan, and topical imiquimod 5%. […] A variety of measuring tools are used to monitor response to treatment. […] The treatments for children supported by the highest quality of evidence (based on epidemiological studies) are phototherapy and the PCMT regimen. […] In summary, PCMT has been shown to be effective in the control of morphea in the short and medium term. However, since morphea is a chronic disease characterized by intermittent outbreaks and periods of remission, new treatment strategies and long-term follow-up studies are needed.
  • #28 Update on the Classification and Treatment of Localized Scleroderma | Actas Dermo-Sifiliográficas
    https://actasdermo.org/es-update-on-classification-treatment-localized-articulo-S157821901300173X
    The current lack of effective assessment tools explains why there are still no randomized double-blind studies to demonstrate the actual efficacy of most of the drugs proposed for the treatment of morphea. […] The drugs most widely accepted as useful in the treatment of this disease are methotrexate and systemic glucocorticoids, almost always administered in combination. […] Improvement, based on the clinical impression of the physician prescribing the treatment, was observed in more than 80% of cases in the majority of those studies. […] The various forms of UV therapy constitute another approach that must be included among the therapies available for the treatment of morphea. […] Physiotherapy is an option worth considering in patients in whom morphea has led to joint contractures and limitations of limb movement, although once again the true usefulness of such therapy has not been demonstrated by any studies. […] Whatever the therapeutic regimen used, all types of morphea tend to progress and recur, particularly when onset occurs during childhood.
  • #29 Morphea in Childhood: An Update | Actas Dermo-Sifiliográficas
    https://actasdermo.org/en-morphea-in-childhood-an-update-articulo-S157821901830088X
    Morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corticosteroids, mycophenolate mofetil, bosentan, and topical imiquimod 5%. […] A variety of measuring tools are used to monitor response to treatment. […] The treatments for children supported by the highest quality of evidence (based on epidemiological studies) are phototherapy and the PCMT regimen. […] In summary, PCMT has been shown to be effective in the control of morphea in the short and medium term. However, since morphea is a chronic disease characterized by intermittent outbreaks and periods of remission, new treatment strategies and long-term follow-up studies are needed.
  • #30 Morphea – MD Searchlight
    https://mdsearchlight.com/skin-problems-and-treatments/morphea/
    Morphea is a relatively uncommon skin condition that both kids and adults could potentially get. The cause of Morphea is thought to be related to an issue with the body’s immune system. However, it’s important for patients to be aware that factors like injuries, exposure to radiation, and even wear and tear from rubbing against something could also play a part. There seems to be a genetic factor as well, meaning that it could run in families, and research suggests that relatives of someone with Morphea might have a higher chance of having other immune system-related conditions. […] Understanding one’s condition is a key part of managing it effectively, and this holds true for Morphea as well. By educating themselves about their condition, patients can better understand what to expect and make informed choices about their treatment options. If a doctor prescribes medications such as corticosteroids, methotrexate, or mycophenolate mofetil, it’s vital that patients also get information from a pharmacist. The pharmacist can explain typical side effects, how these medications might interact with other drugs, and the need for birth control methods to prevent pregnancy while on these medications. This can help increase patients’ willingness and ability to follow their prescribed treatment plan.
  • #31 Morphea – MD Searchlight
    https://mdsearchlight.com/skin-problems-and-treatments/morphea/
    Morphea is a relatively uncommon skin condition that both kids and adults could potentially get. The cause of Morphea is thought to be related to an issue with the body’s immune system. However, it’s important for patients to be aware that factors like injuries, exposure to radiation, and even wear and tear from rubbing against something could also play a part. There seems to be a genetic factor as well, meaning that it could run in families, and research suggests that relatives of someone with Morphea might have a higher chance of having other immune system-related conditions. […] Understanding one’s condition is a key part of managing it effectively, and this holds true for Morphea as well. By educating themselves about their condition, patients can better understand what to expect and make informed choices about their treatment options. If a doctor prescribes medications such as corticosteroids, methotrexate, or mycophenolate mofetil, it’s vital that patients also get information from a pharmacist. The pharmacist can explain typical side effects, how these medications might interact with other drugs, and the need for birth control methods to prevent pregnancy while on these medications. This can help increase patients’ willingness and ability to follow their prescribed treatment plan.
  • #32 Morphea of the face
    https://www.aboutkidshealth.ca/morphea-of-the-face
    Most of the complications related to the disease can be decreased by treating it early. Follow the health-care teams recommendations for screening of associated complications (eye, brain, psychological). […] Treatment can reduce the inflammation, stop lesions from spreading and prevent new lesions from appearing.
  • #33 Morphea of the face
    https://www.aboutkidshealth.ca/morphea-of-the-face
    Most of the complications related to the disease can be decreased by treating it early. Follow the health-care teams recommendations for screening of associated complications (eye, brain, psychological). […] Treatment can reduce the inflammation, stop lesions from spreading and prevent new lesions from appearing.
  • #34 Update on the Classification and Treatment of Localized Scleroderma | Actas Dermo-Sifiliográficas
    https://actasdermo.org/es-update-on-classification-treatment-localized-articulo-S157821901300173X
    The current lack of effective assessment tools explains why there are still no randomized double-blind studies to demonstrate the actual efficacy of most of the drugs proposed for the treatment of morphea. […] The drugs most widely accepted as useful in the treatment of this disease are methotrexate and systemic glucocorticoids, almost always administered in combination. […] Improvement, based on the clinical impression of the physician prescribing the treatment, was observed in more than 80% of cases in the majority of those studies. […] The various forms of UV therapy constitute another approach that must be included among the therapies available for the treatment of morphea. […] Physiotherapy is an option worth considering in patients in whom morphea has led to joint contractures and limitations of limb movement, although once again the true usefulness of such therapy has not been demonstrated by any studies. […] Whatever the therapeutic regimen used, all types of morphea tend to progress and recur, particularly when onset occurs during childhood.
  • #35 Morphea: The 2023 update
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9969991/
    The correct assessment of disease severity is a crucial step in the evaluation of all patients with morphea, in particular in pediatric variants. An incorrect severity assessment may lead to a delayed initiation of appropriate systemic treatment, and thus to irreversible physical and functional disabilities. […] Disease activity assessment based on current validated clinical scores is a crucial step in the initial evaluation of patients with morphea. A late diagnosis or an incorrect severity assessment may lead to a delay of appropriate treatment, and thus to physical and functional disabilities as well as decreased quality of life. This applies in particular to pediatric morphea, especially the linear and deep types, where initiating adequate systemics is pivotal for achieving disease control and reducing subsequent damage. […] In addition, childhood morphea is associated with a more severe disease course and higher risk of relapse, the latter occurring even after years of remission.
  • #36 Morphea in Childhood: An Update | Actas Dermo-Sifiliográficas
    https://actasdermo.org/en-morphea-in-childhood-an-update-articulo-S157821901830088X
    Morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corticosteroids, mycophenolate mofetil, bosentan, and topical imiquimod 5%. […] A variety of measuring tools are used to monitor response to treatment. […] The treatments for children supported by the highest quality of evidence (based on epidemiological studies) are phototherapy and the PCMT regimen. […] In summary, PCMT has been shown to be effective in the control of morphea in the short and medium term. However, since morphea is a chronic disease characterized by intermittent outbreaks and periods of remission, new treatment strategies and long-term follow-up studies are needed.
  • #37 Juvenile Localized Scleroderma Symptoms & Causes
    https://my.clevelandclinic.org/health/diseases/14857-juvenile-localized-scleroderma
    Theres no known way to prevent juvenile localized scleroderma since the cause is unknown. […] The goal of juvenile localized scleroderma treatment is to stop inflammation, keep the condition from getting worse and reduce the formation of hard (fibrous) tissue. Treatment is unique to each child and depends on how severe their diagnosis is. […] Your child will have the most positive outlook if their condition receives treatment early, when they first get their diagnosis.
  • #38 Juvenile Localized Scleroderma Symptoms & Causes
    https://my.clevelandclinic.org/health/diseases/14857-juvenile-localized-scleroderma
    Theres no known way to prevent juvenile localized scleroderma since the cause is unknown. […] The goal of juvenile localized scleroderma treatment is to stop inflammation, keep the condition from getting worse and reduce the formation of hard (fibrous) tissue. Treatment is unique to each child and depends on how severe their diagnosis is. […] Your child will have the most positive outlook if their condition receives treatment early, when they first get their diagnosis.
  • #39 Morphea: Evidence-based recommendations for treatment – Indian Journal of Dermatology, Venereology and Leprology
    https://ijdvl.com/morphea-evidence-based-recommendations-for-treatment/
    Morphea typically goes through two stages: an active (inflammatory) stage and a „burnt out” stage. Treatment is targeted at the active phase, in the hope of stabilizing the size of current lesions and preventing the occurrence of new lesions. […] Patients need to recognize that the involved skin will never look completely normal. They must be counseled that treatment is aimed at active disease in the hopes of preventing enlargement of already-present lesions and the development of new lesions. Burnt-out disease is unlikely to improve with immunosuppression and, therefore, the risks of these medications are not warranted in burnt-out disease. […] Patients with limited plaque morphea are at very low risk of facial deformity, limb length discrepancy and contractures and therefore should be treated with topical agents whenever possible. Based on the available data, active limited plaque morphea should be primarily treated with topical tacrolimus twice daily. If no response is seen after 8 weeks, therapy may be changed to lesion limited-phototherapy (NB-UVB, BB-UVA, UVA1, or topical psoralen and UVA), twice-daily occluded calipotriene, a combination of calcipotriol and betamethasone dipropionate once to twice a day or thrice-weekly topical imiquimod.
  • #40 Morphea: The 2023 update
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9969991/
    Morphea, also known as localized scleroderma, is a chronic inflammatory connective tissue disorder with variable clinical presentations, that affects both adults and children. […] Since the disease may progress to permanent cosmetic and functional sequelae, it is crucial to properly assess the disease activity and to initiate promptly the adequate treatment, thus preventing subsequent damage. […] The current therapeutic options are, however, limited, not disease-specific and their long-term use is often associated with several adverse events. […] Herein, we review the various clinical presentations of morphea, the most recent advances regarding its pathogenesis, as well as the many challenges that the clinicians encounter in disease diagnosis, severity assessment and appropriate treatment selection.
  • #41 Update on the Classification and Treatment of Localized Scleroderma | Actas Dermo-Sifiliográficas
    https://actasdermo.org/es-update-on-classification-treatment-localized-articulo-S157821901300173X
    The current lack of effective assessment tools explains why there are still no randomized double-blind studies to demonstrate the actual efficacy of most of the drugs proposed for the treatment of morphea. […] The drugs most widely accepted as useful in the treatment of this disease are methotrexate and systemic glucocorticoids, almost always administered in combination. […] Improvement, based on the clinical impression of the physician prescribing the treatment, was observed in more than 80% of cases in the majority of those studies. […] The various forms of UV therapy constitute another approach that must be included among the therapies available for the treatment of morphea. […] Physiotherapy is an option worth considering in patients in whom morphea has led to joint contractures and limitations of limb movement, although once again the true usefulness of such therapy has not been demonstrated by any studies. […] Whatever the therapeutic regimen used, all types of morphea tend to progress and recur, particularly when onset occurs during childhood.